Standard Biotools (LAB) Total Current Liabilities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Total Current Liabilities data on file, last reported at $42.2 million in Q1 2026.

• Quarterly Total Current Liabilities fell 24.95% year-over-year to $42.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.2 million (down 24.95% YoY) and the FY2025 annual result came in at $108.3 million, up 64.36% from the prior year.
• Total Current Liabilities declined to $42.2 million in Q1 2026 per LAB's latest filing, from $108.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $123.8 million in Q2 2024 and bottomed at $42.2 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $56.2 million (2025), against an average of $75.1 million.
• The widest annual swing landed in 2024, when Total Current Liabilities jumped 177.6%; it then tumbled 53.74% in 2025.
• Tracing LAB's Total Current Liabilities over 5 years: stood at $43.4 million in 2022, then surged by 151.66% to $109.3 million in 2023, then plunged by 39.73% to $65.9 million in 2024, then jumped by 64.36% to $108.3 million in 2025, then tumbled by 61.03% to $42.2 million in 2026.
• Per Business Quant, the three latest LAB Total Current Liabilities figures stand at $42.2 million (Q1 2026), $108.3 million (Q4 2025), and $108.0 million (Q3 2025).

Peer Comparison